EU Expert Panel Warns of Clinical Impact from Shortage of Critical Cardiac Cannulae and Catheters

A European Circulatory System Expert Panel has issued scientific advice to the European Commission concerning a possible Union-wide derogation under Article 59(3) of the Medical Device Regulation (MDR) for several cardiac cannulae and catheters manufactured by Andocor NV.

The advice, delivered on 9 June 2026, was requested by the European Commission’s DG SANTE in the context of potential supply shortages affecting devices used in cardiopulmonary bypass, extracorporeal circulation and cardiac surgery.

Devices Covered by the Request

The Commission’s request concerns the following Andocor NV devices:

  • Arterial Cannula Reinforced;

  • Arterial Cannula Non-Reinforced;

  • Aortic Catheter;

  • Flex Line Venous Catheter;

  • Flex Line Two Stage Venous Catheter.

These products are used to establish arterial perfusion and venous drainage during cardiopulmonary bypass.

Possible Union-Wide Derogation Under Article 59 MDR

Under Article 59 MDR, a national competent authority may authorise the placing on the market of a specific device where conformity assessment has not yet been completed, provided that its use is in the interest of public health, patient safety or patient health.

In exceptional cases, the European Commission may extend such a national authorisation to the entire Union for a limited period.

The Commission is considering whether the existing national derogations for these devices should be extended across the EU.

Why the Supply Problem Emerged

The devices had originally been certified as Class IIa devices under the Medical Devices Directive (MDD).

Following the closure of the original Notified Body in 2020, the manufacturer obtained a new MDD certificate from TÜV NORD.

However, on 1 March 2023, TÜV NORD restricted the certificate after concluding that the devices should instead have been classified as Class III under the MDD.

As a result, the manufacturer could no longer rely on MDR transitional provisions and was prevented from continuing to place the products on the EU market.

MDR Conformity Assessment Is Underway

Andocor has since initiated an MDR conformity assessment procedure with TÜV SÜD.

According to the expert panel document, the process is expected to take approximately 9 to 18 months.

During this period, several Member States have used national derogations to maintain continuity of supply.

Multiple Member States Have Already Granted Derogations

The Commission notes that several Member States have granted derogations covering these arterial, aortic and venous cannulae and catheters.

The document identifies derogations in countries including:

  • Austria;

  • Belgium;

  • France;

  • Germany;

  • Greece;

  • Luxembourg;

  • Slovakia;

  • Spain;

  • Sweden;

  • the Netherlands.

The existence of multiple national derogations reflects the concern that insufficient supply could affect critical clinical services.

Alternatives Exist — but Availability Is Uneven

The expert panel acknowledges that alternative products with similar intended purposes are available from several manufacturers.

However, it stresses that availability is not uniform across the EU.

Some Member States have already experienced supply constraints, and wider supply-chain disruption may limit the real-world substitutability of alternative devices.

Substitution Is Not Always Straightforward

The expert panel notes that replacing one cannula or catheter with another from a different manufacturer may involve practical differences in:

  • flexibility;

  • reinforcement;

  • tip configuration;

  • flow characteristics.

These characteristics can matter in specific surgical procedures.

Cardiac teams also tend to work with devices and systems with which they are already familiar, meaning product substitution may require changes in technique or workflow.

Devices Perform an Essential Function

The panel concludes that these types of devices perform a critical and essential function in cardiac surgery.

They enable:

  • arterial perfusion;

  • venous drainage;

  • establishment of cardiopulmonary bypass.

Without appropriate cannulation, the majority of open-heart procedures cannot proceed as planned.

Some Patient Groups Are Particularly Vulnerable

The expert panel identifies several settings where supply disruption could be especially critical:

  • urgent and emergency cardiac cases;

  • paediatric and congenital surgery;

  • complex procedures;

  • minimally invasive procedures;

  • centres with limited procurement flexibility.

These areas may be less able to absorb shortages or switch rapidly to alternatives.

Shortage Could Lead to Delays and Cancellations

According to the panel, insufficient availability of these devices could have an immediate and very serious impact on clinical practice.

Potential consequences include:

  • postponement of planned cardiac procedures;

  • cancellation of procedures;

  • reduced capacity for urgent surgery;

  • longer patient waiting times;

  • transfer of patients between hospitals.

Patient Outcomes Could Worsen

For chronic cardiac conditions, delays in surgery may result in:

  • deterioration in health;

  • increased risk of complications;

  • worsening prognosis.

For acute conditions, delays may have serious or even fatal consequences.

Use of Less Familiar Alternatives May Increase Complexity

Where substitute products are available, clinicians would be expected to use them.

However, if supply problems affect multiple manufacturers simultaneously, teams may need to use:

  • less familiar devices;

  • suboptimal configurations.

The expert panel notes that this could increase procedural complexity and reduce efficiency.

No Specific Safety Concerns Identified

The panel states that it is not aware of specific safety issues associated with the Andocor devices based on the information available.

This is particularly notable because the products have been used in clinical practice for more than two decades.

The known risks associated with arterial and venous cannulation for cardiopulmonary bypass are considered well established.

More Than 20 Years of Clinical Use

The expert panel notes that these devices have been on the market for more than 20 years.

The Commission’s supporting documentation further states that they have been marketed for more than 27 years and have not been associated with significant vigilance concerns based on the available information.

New Evidence on Alternative Supply

In 2026, the manufacturer provided additional information suggesting that alternative suppliers were also experiencing shortages.

The submission included:

  • 39 letters from healthcare professionals and institutions;

  • 19 letters from distributors.

These documents reportedly described difficulties obtaining suitable alternatives and concerns regarding delays or cancellation of urgent procedures.

Member States Also Raised Supply Concerns

A second consultation with Member States further identified:

  • potential critical supply issues;

  • concerns about continuity of supply;

  • risks to patient care.

Some Member States considered that the situation could justify a Union-wide derogation in the interest of public health.

However, the Commission noted that the overall evidence regarding availability of alternatives remained inconclusive.

Expert Panel Asked Three Main Questions

The Commission requested advice on three central issues:

  1. Whether suitable alternative devices are sufficiently available across the Union.

  2. What the consequences would be if these devices were unavailable.

  3. Whether any safety concerns are known for the devices.

Clinical Importance Supports Regulatory Attention

The expert panel’s response makes a clear distinction between the existence of theoretical alternatives and their actual availability and suitability in clinical practice.

While alternatives may exist on the European market, the panel does not consider this sufficient to assume that all hospitals or Member States can obtain appropriate substitutes when needed.

Importance of Article 59 as a Supply Continuity Mechanism

This case illustrates the role of Article 59 MDR as a regulatory mechanism for exceptional situations.

Derogations can allow temporary market access where normal conformity assessment requirements are not yet fully completed but withholding a device could create a greater public-health or patient-safety risk.

A Union-wide derogation under Article 59(3) can also help prevent fragmented national approaches where the same supply problem affects multiple Member States.

Implications for Manufacturers

The case highlights several regulatory lessons for medical device manufacturers.

These include the importance of:

  • ensuring correct classification;

  • maintaining continuity of conformity assessment;

  • monitoring Notified Body status;

  • preparing early for MDR transition;

  • assessing supply continuity risks;

  • maintaining evidence supporting derogation requests where necessary.

Classification Errors Can Have Major Market Consequences

The supply disruption arose after the devices were reassessed as requiring Class III rather than Class IIa classificationunder the MDD.

This shows how a classification issue can affect:

  • certificate validity;

  • transitional MDR eligibility;

  • continued market access;

  • supply continuity;

  • patient care.

For critical products, the consequences can extend beyond the manufacturer and affect healthcare systems across multiple countries.

Implications for Competent Authorities

The case also demonstrates the importance of regulatory coordination between:

  • Member State competent authorities;

  • the European Commission;

  • Expert Panels;

  • Notified Bodies;

  • manufacturers;

  • healthcare providers.

Where shortages involve essential medical devices, decisions need to balance conformity assessment requirements against the clinical consequences of removing products from the market.

A Wider Supply-Security Question Under the MDR

The expert panel advice highlights a broader issue under the MDR: technically available alternatives do not necessarily mean clinically accessible alternatives.

Supply-chain capacity, local procurement, clinical familiarity and device-specific performance characteristics may all affect whether substitution is genuinely possible.

For critical devices, these factors may become relevant when assessing public-health implications of regulatory disruption.

Próximo
Próximo

MDSAP Updates Audit Time Determination Procedure for Medical Device Manufacturers